[{
  "_id": {
    "$oid": "68246feda116cc7161242716"
  },
  "safetyreportversion": 2,
  "safetyreportid": 19520083,
  "primarysourcecountry": "US",
  "occurcountry": "US",
  "transmissiondateformat": 102,
  "transmissiondate": {
    "$date": "2024-04-10T00:00:00.000Z"
  },
  "reporttype": 1,
  "serious": 2,
  "seriousnessdeath": 2,
  "seriousnesslifethreatening": 2,
  "seriousnesshospitalization": 2,
  "seriousnessdisabling": 2,
  "seriousnesscongenitalanomali": 2,
  "seriousnessother": 2,
  "receivedateformat": 102,
  "receivedate": {
    "$date": "2021-07-12T00:00:00.000Z"
  },
  "receiptdateformat": 102,
  "receiptdate": {
    "$date": "2024-03-15T00:00:00.000Z"
  },
  "fulfillexpeditecriteria": 2,
  "companynumb": "US-SECURA BIO, INC.-2021US002331",
  "primarysource": {
    "reportercountry": "US",
    "qualification": 5
  },
  "sender": {
    "sendertype": 2,
    "senderorganization": "FDA-Public Use"
  },
  "receiver": {
    "receivertype": 6,
    "receiverorganization": "FDA"
  },
  "patient": {
    "reaction": [
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Fatigue",
        "reactionoutcome": 6
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Constipation",
        "reactionoutcome": 6
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Dyspnoea",
        "reactionoutcome": 6
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Blood sodium decreased",
        "reactionoutcome": 6
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Hypotension",
        "reactionoutcome": 6
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Drug interaction",
        "reactionoutcome": 6
      }
    ],
    "drug": [
      {
        "drugcharacterization": 1,
        "medicinalproduct": "COPIKTRA",
        "drugbatchnumb": "1697765A",
        "drugauthorizationnumb": 211155,
        "drugstructuredosagenumb": 75,
        "drugstructuredosageunit": 3,
        "drugseparatedosagenumb": 2,
        "drugintervaldosageunitnumb": 1,
        "drugintervaldosagedefinition": 804,
        "drugdosagetext": "75 MG, BID",
        "drugdosageform": "Capsule",
        "drugadministrationroute": 48,
        "drugindication": "Non-Hodgkin^s lymphoma",
        "actiondrug": 5,
        "drugrecurreadministration": 3,
        "drugadditional": 3,
        "activesubstance": {
          "activesubstancename": "DUVELISIB"
        },
        "openfda": {
          "application_number": [
            "NDA211155"
          ],
          "brand_name": [
            "COPIKTRA"
          ],
          "generic_name": [
            "DUVELISIB"
          ],
          "manufacturer_name": [
            "Secura Bio, Inc"
          ],
          "product_ndc": [
            "73116-215",
            "73116-225"
          ],
          "product_type": [
            "HUMAN PRESCRIPTION DRUG"
          ],
          "route": [
            "ORAL"
          ],
          "substance_name": [
            "DUVELISIB"
          ],
          "rxcui": [
            "2058514",
            "2058520",
            "2058523",
            "2058525"
          ],
          "spl_id": [
            "de5c746e-bd30-4b3c-a473-b8fe1f70153c"
          ],
          "spl_set_id": [
            "e3c5ac56-e1f6-473a-bc73-687836534780"
          ],
          "package_ndc": [
            "73116-225-28",
            "73116-225-56",
            "73116-215-28",
            "73116-215-56"
          ],
          "unii": [
            "610V23S0JI"
          ]
        }
      },
      {
        "drugcharacterization": 1,
        "medicinalproduct": "AMLODIPINE",
        "drugadministrationroute": 65,
        "drugindication": "Product used for unknown indication",
        "actiondrug": 5,
        "drugrecurreadministration": 3,
        "drugadditional": 3,
        "activesubstance": {
          "activesubstancename": "AMLODIPINE BESYLATE"
        },
        "openfda": {
          "application_number": [
            "NDA214439",
            "NDA211340",
            "ANDA215035"
          ],
          "brand_name": [
            "NORLIQVA",
            "KATERZIA",
            "AMLODIPINE"
          ],
          "generic_name": [
            "AMLODIPINE"
          ],
          "manufacturer_name": [
            "CMP Pharma, Inc.",
            "Azurity Pharmaceuticals, Inc.",
            "Amneal Pharmaceuticals NY LLC"
          ],
          "product_ndc": [
            "46287-035",
            "52652-5001",
            "69238-2026"
          ],
          "product_type": [
            "HUMAN PRESCRIPTION DRUG"
          ],
          "route": [
            "ORAL"
          ],
          "substance_name": [
            "AMLODIPINE",
            "AMLODIPINE BENZOATE"
          ],
          "rxcui": [
            "2599173",
            "2599179",
            "2184120",
            "2184126"
          ],
          "spl_id": [
            "63a6bb49-fb68-4351-be5f-a6b6e8f6b540",
            "78965c75-1ba7-48f0-bc14-029d5bb34f88",
            "f18fa3f2-2d8f-499f-9708-3748fee89eb3"
          ],
          "spl_set_id": [
            "c1730a51-4383-4c61-a9a1-7e1326bd0abe",
            "df673a4d-acb8-444c-a472-c87ab8cbd366",
            "8394e577-3b64-4655-86b8-b757126672c9"
          ],
          "package_ndc": [
            "46287-035-15",
            "52652-5001-1",
            "69238-2026-7"
          ],
          "nui": [
            "N0000000069",
            "N0000175421",
            "N0000175566",
            "M0006414",
            "N0000190114"
          ],
          "pharm_class_moa": [
            "Calcium Channel Antagonists [MoA]",
            "Cytochrome P450 3A Inhibitors [MoA]"
          ],
          "pharm_class_epc": [
            "Dihydropyridine Calcium Channel Blocker [EPC]",
            "Calcium Channel Blocker [EPC]"
          ],
          "pharm_class_cs": [
            "Dihydropyridines [CS]"
          ],
          "unii": [
            "1J444QC288",
            "XD75TQ8A2P"
          ]
        }
      }
    ]
  }
},
{
  "_id": {
    "$oid": "68246feda116cc7161242717"
  },
  "safetyreportversion": 2,
  "safetyreportid": 19529532,
  "primarysourcecountry": "DE",
  "occurcountry": "DE",
  "transmissiondateformat": 102,
  "transmissiondate": {
    "$date": "2024-04-10T00:00:00.000Z"
  },
  "reporttype": 1,
  "serious": 1,
  "seriousnessdeath": 1,
  "seriousnesslifethreatening": 2,
  "seriousnesshospitalization": 2,
  "seriousnessdisabling": 2,
  "seriousnesscongenitalanomali": 2,
  "seriousnessother": 1,
  "receivedateformat": 102,
  "receivedate": {
    "$date": "2021-07-13T00:00:00.000Z"
  },
  "receiptdateformat": 102,
  "receiptdate": {
    "$date": "2024-01-23T00:00:00.000Z"
  },
  "fulfillexpeditecriteria": 1,
  "companynumb": "DE-PFIZER INC-2021817569",
  "duplicate": 1,
  "reportduplicate": [
    {
      "duplicatesource": "PFIZER INC",
      "duplicatenumb": "DE-PFIZER INC-2021805342"
    },
    {
      "duplicatesource": "PFIZER INC",
      "duplicatenumb": "JP-PFIZER INC-PV202400005237"
    }
  ],
  "primarysource": {
    "reportercountry": "DE",
    "qualification": 1,
    "literaturereference": "Ozdirik, B.. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.. Medicine. 2021;100 (24):e26377"
  },
  "sender": {
    "sendertype": 2,
    "senderorganization": "FDA-Public Use"
  },
  "receiver": {
    "receivertype": 6,
    "receiverorganization": "FDA"
  },
  "patient": {
    "patientonsetage": 70,
    "patientonsetageunit": 801,
    "patientsex": 2,
    "reaction": [
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Encephalitis",
        "reactionoutcome": 5
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Neurological symptom",
        "reactionoutcome": 5
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Multiple organ dysfunction syndrome",
        "reactionoutcome": 5
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Off label use",
        "reactionoutcome": 6
      }
    ],
    "drug": [
      {
        "drugcharacterization": 1,
        "medicinalproduct": "BEVACIZUMAB",
        "drugauthorizationnumb": 761099,
        "drugstructuredosagenumb": 15,
        "drugstructuredosageunit": 7,
        "drugdosagetext": "15 MG/KG OVER 90 MINUTES",
        "drugindication": "Hepatocellular carcinoma",
        "actiondrug": 6,
        "drugadditional": 4,
        "activesubstance": {
          "activesubstancename": "BEVACIZUMAB"
        },
        "openfda": {
          "application_number": [
            "BLA761198",
            "BLA125085"
          ],
          "brand_name": [
            "AVZIVI TNJN",
            "AVASTIN"
          ],
          "generic_name": [
            "BEVACIZUMAB"
          ],
          "manufacturer_name": [
            "Bio-Thera Solutions, Ltd.",
            "Genentech, Inc."
          ],
          "product_ndc": [
            "82143-001",
            "82143-002",
            "50242-060",
            "50242-061"
          ],
          "product_type": [
            "HUMAN PRESCRIPTION DRUG"
          ],
          "route": [
            "INTRAVENOUS"
          ],
          "substance_name": [
            "BEVACIZUMAB-TNJN",
            "BEVACIZUMAB"
          ],
          "rxcui": [
            "2700735",
            "2700742",
            "2700744",
            "2700745",
            "1657066",
            "1657068",
            "1657073",
            "1657074"
          ],
          "spl_id": [
            "24041767-230c-9a58-e063-6394a90ad576",
            "8debebf6-af94-4ba7-8d67-c801f4ea27eb"
          ],
          "spl_set_id": [
            "a3976cf9-9edb-4ca2-9375-9bcd2e32f5b4",
            "939b5d1f-9fb2-4499-80ef-0607aa6b114e"
          ],
          "package_ndc": [
            "82143-001-01",
            "82143-002-01",
            "50242-060-01",
            "50242-060-10",
            "50242-061-01",
            "50242-061-10"
          ],
          "unii": [
            "2S9ZZM9Q9V"
          ],
          "nui": [
            "N0000193543",
            "N0000178291",
            "N0000193542"
          ],
          "pharm_class_epc": [
            "Vascular Endothelial Growth Factor Inhibitor [EPC]"
          ],
          "pharm_class_moa": [
            "Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]",
            "Vascular Endothelial Growth Factor Inhibitors [MoA]"
          ]
        }
      },
      {
        "drugcharacterization": 1,
        "medicinalproduct": "ATEZOLIZUMAB",
        "drugstructuredosagenumb": 1200,
        "drugstructuredosageunit": 3,
        "drugdosagetext": "1200 MG, OVER 2 HOURS",
        "drugindication": "Hepatocellular carcinoma",
        "actiondrug": 6,
        "drugadditional": 4,
        "activesubstance": {
          "activesubstancename": "ATEZOLIZUMAB"
        },
        "openfda": {
          "application_number": [
            "BLA761034"
          ],
          "brand_name": [
            "TECENTRIQ"
          ],
          "generic_name": [
            "ATEZOLIZUMAB"
          ],
          "manufacturer_name": [
            "Genentech, Inc."
          ],
          "product_ndc": [
            "50242-917",
            "50242-918"
          ],
          "product_type": [
            "HUMAN PRESCRIPTION DRUG"
          ],
          "route": [
            "INTRAVENOUS"
          ],
          "substance_name": [
            "ATEZOLIZUMAB"
          ],
          "rxcui": [
            "1792780",
            "1792785",
            "2119695",
            "2119696"
          ],
          "spl_id": [
            "f4fe4626-4d6c-4c50-9d52-51aae17f27d6"
          ],
          "spl_set_id": [
            "6fa682c9-a312-4932-9831-f286908660ee"
          ],
          "package_ndc": [
            "50242-917-01",
            "50242-917-86",
            "50242-918-01"
          ],
          "nui": [
            "N0000191260",
            "N0000191259",
            "M0556300",
            "M0001357",
            "M0001352"
          ],
          "pharm_class_epc": [
            "Programmed Death Receptor-1 Blocking Antibody [EPC]"
          ],
          "pharm_class_moa": [
            "Programmed Death Receptor-1-directed Antibody Interactions [MoA]"
          ],
          "pharm_class_cs": [
            "Antibodies, Monoclonal, Humanized [CS]",
            "Antibodies, Monoclonal [CS]",
            "Antibodies [CS]"
          ],
          "unii": [
            "52CMI0WC3Y"
          ]
        }
      }
    ]
  }
},
{
  "_id": {
    "$oid": "68246feda116cc7161242718"
  },
  "safetyreportversion": 3,
  "safetyreportid": 19652409,
  "primarysourcecountry": "US",
  "occurcountry": "US",
  "transmissiondateformat": 102,
  "transmissiondate": {
    "$date": "2024-04-09T00:00:00.000Z"
  },
  "reporttype": 1,
  "serious": 2,
  "seriousnessdeath": 2,
  "seriousnesslifethreatening": 2,
  "seriousnesshospitalization": 2,
  "seriousnessdisabling": 2,
  "seriousnesscongenitalanomali": 2,
  "seriousnessother": 2,
  "receivedateformat": 102,
  "receivedate": {
    "$date": "2021-08-03T00:00:00.000Z"
  },
  "receiptdateformat": 102,
  "receiptdate": {
    "$date": "2024-02-01T00:00:00.000Z"
  },
  "fulfillexpeditecriteria": 2,
  "companynumb": "US-SA-SAC20210729000884",
  "duplicate": 1,
  "reportduplicate": [
    {
      "duplicatesource": "SA",
      "duplicatenumb": "US-SA-SAC20220107000855"
    },
    {
      "duplicatesource": "PORTAL ID",
      "duplicatenumb": "SanofiPVPortal20220107000279"
    },
    {
      "duplicatesource": "AE Record ID",
      "duplicatenumb": "AE00539448"
    },
    {
      "duplicatesource": "SA",
      "duplicatenumb": "US-SA-SAC20210729000884"
    },
    {
      "duplicatesource": "PORTAL ID",
      "duplicatenumb": "SanofiPVPortal20210728000780"
    },
    {
      "duplicatesource": "PORTAL ID",
      "duplicatenumb": "SanofiPVPortal20240122000551"
    }
  ],
  "primarysource": {
    "reportercountry": "US",
    "qualification": 1
  },
  "sender": {
    "sendertype": 2,
    "senderorganization": "FDA-Public Use"
  },
  "receiver": {
    "receivertype": 6,
    "receiverorganization": "FDA"
  },
  "patient": {
    "patientonsetage": 83,
    "patientonsetageunit": 801,
    "patientagegroup": 6,
    "patientsex": 1,
    "reaction": [
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Erythema",
        "reactionoutcome": 6
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Rash",
        "reactionoutcome": 6
      },
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Inappropriate schedule of product administration",
        "reactionoutcome": 6
      }
    ],
    "drug": [
      {
        "drugcharacterization": 1,
        "medicinalproduct": "DUPIXENT",
        "drugauthorizationnumb": 761055,
        "drugstructuredosagenumb": 300,
        "drugstructuredosageunit": 3,
        "drugseparatedosagenumb": 1,
        "drugintervaldosageunitnumb": 2,
        "drugintervaldosagedefinition": 803,
        "drugdosagetext": "300 MG, QOW",
        "drugdosageform": "Solution for injection",
        "drugadministrationroute": 58,
        "drugindication": "Dermatitis atopic",
        "drugstartdateformat": 610,
        "drugstartdate": {
          "$date": "2021-07-01T00:00:00.000Z"
        },
        "actiondrug": 4,
        "activesubstance": {
          "activesubstancename": "DUPILUMAB"
        },
        "openfda": {
          "application_number": [
            "BLA761055"
          ],
          "brand_name": [
            "DUPIXENT"
          ],
          "generic_name": [
            "DUPILUMAB"
          ],
          "manufacturer_name": [
            "sanofi-aventis U.S. LLC"
          ],
          "product_ndc": [
            "0024-5911",
            "0024-5914",
            "0024-5918",
            "0024-5915",
            "0024-5919"
          ],
          "product_type": [
            "HUMAN PRESCRIPTION DRUG"
          ],
          "route": [
            "SUBCUTANEOUS"
          ],
          "substance_name": [
            "DUPILUMAB"
          ],
          "spl_id": [
            "acdeeda1-b75b-4207-8a41-d8287ac542e1"
          ],
          "spl_set_id": [
            "595f437d-2729-40bb-9c62-c8ece1f82780"
          ],
          "package_ndc": [
            "0024-5914-00",
            "0024-5914-01",
            "0024-5914-20",
            "0024-5914-02",
            "0024-5918-00",
            "0024-5918-01",
            "0024-5918-20",
            "0024-5918-02",
            "0024-5915-00",
            "0024-5915-02",
            "0024-5915-01",
            "0024-5915-20",
            "0024-5919-00",
            "0024-5919-02",
            "0024-5919-01",
            "0024-5919-20",
            "0024-5911-00",
            "0024-5911-02",
            "0024-5911-01",
            "0024-5911-20"
          ],
          "nui": [
            "N0000193342",
            "N0000193341",
            "M0001357"
          ],
          "pharm_class_epc": [
            "Interleukin-4 Receptor alpha Antagonist [EPC]"
          ],
          "pharm_class_moa": [
            "Interleukin 4 Receptor alpha Antagonists [MoA]"
          ],
          "pharm_class_cs": [
            "Antibodies, Monoclonal [CS]"
          ],
          "unii": [
            "420K487FSG"
          ]
        }
      }
    ],
    "summary": {
      "narrativeincludeclinical": "CASE EVENT DATE: 20211209",
      "case_event_date_extracted": {
        "$date": "2021-12-09T00:00:00.000Z"
      }
    }
  }
},
{
  "_id": {
    "$oid": "68246feda116cc7161242719"
  },
  "safetyreportversion": 2,
  "safetyreportid": 19773719,
  "primarysourcecountry": "US",
  "occurcountry": "US",
  "transmissiondateformat": 102,
  "transmissiondate": {
    "$date": "2024-04-10T00:00:00.000Z"
  },
  "reporttype": 1,
  "serious": 2,
  "seriousnessdeath": 2,
  "seriousnesslifethreatening": 2,
  "seriousnesshospitalization": 2,
  "seriousnessdisabling": 2,
  "seriousnesscongenitalanomali": 2,
  "seriousnessother": 2,
  "receivedateformat": 102,
  "receivedate": {
    "$date": "2021-09-01T00:00:00.000Z"
  },
  "receiptdateformat": 102,
  "receiptdate": {
    "$date": "2024-03-26T00:00:00.000Z"
  },
  "fulfillexpeditecriteria": 2,
  "companynumb": "US-SA-SAC20210827000741",
  "duplicate": 1,
  "reportduplicate": [
    {
      "duplicatesource": "SA",
      "duplicatenumb": "US-SA-SAC20210827000741"
    },
    {
      "duplicatesource": "PORTAL ID",
      "duplicatenumb": "SanofiPVPortal20210824000774"
    },
    {
      "duplicatesource": "SA",
      "duplicatenumb": "US-SA-SAC20240320001243"
    },
    {
      "duplicatesource": "PORTAL ID",
      "duplicatenumb": "SanofiPVPortal20240319001187"
    }
  ],
  "primarysource": {
    "reportercountry": "US",
    "qualification": 1
  },
  "sender": {
    "sendertype": 2,
    "senderorganization": "FDA-Public Use"
  },
  "receiver": {
    "receivertype": 6,
    "receiverorganization": "FDA"
  },
  "patient": {
    "patientagegroup": 5,
    "patientsex": 1,
    "reaction": [
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Abnormal weight gain",
        "reactionoutcome": 6
      }
    ],
    "drug": [
      {
        "drugcharacterization": 1,
        "medicinalproduct": "DUPIXENT",
        "drugauthorizationnumb": 761055,
        "drugstructuredosagenumb": 300,
        "drugstructuredosageunit": 3,
        "drugseparatedosagenumb": 1,
        "drugintervaldosageunitnumb": 2,
        "drugintervaldosagedefinition": 803,
        "drugdosagetext": "300 MG, QOW",
        "drugdosageform": "Solution for injection",
        "drugadministrationroute": 58,
        "drugindication": "Dermatitis atopic",
        "actiondrug": 5,
        "drugadditional": 3,
        "activesubstance": {
          "activesubstancename": "DUPILUMAB"
        },
        "openfda": {
          "application_number": [
            "BLA761055"
          ],
          "brand_name": [
            "DUPIXENT"
          ],
          "generic_name": [
            "DUPILUMAB"
          ],
          "manufacturer_name": [
            "sanofi-aventis U.S. LLC"
          ],
          "product_ndc": [
            "0024-5911",
            "0024-5914",
            "0024-5918",
            "0024-5915",
            "0024-5919"
          ],
          "product_type": [
            "HUMAN PRESCRIPTION DRUG"
          ],
          "route": [
            "SUBCUTANEOUS"
          ],
          "substance_name": [
            "DUPILUMAB"
          ],
          "spl_id": [
            "acdeeda1-b75b-4207-8a41-d8287ac542e1"
          ],
          "spl_set_id": [
            "595f437d-2729-40bb-9c62-c8ece1f82780"
          ],
          "package_ndc": [
            "0024-5914-00",
            "0024-5914-01",
            "0024-5914-20",
            "0024-5914-02",
            "0024-5918-00",
            "0024-5918-01",
            "0024-5918-20",
            "0024-5918-02",
            "0024-5915-00",
            "0024-5915-02",
            "0024-5915-01",
            "0024-5915-20",
            "0024-5919-00",
            "0024-5919-02",
            "0024-5919-01",
            "0024-5919-20",
            "0024-5911-00",
            "0024-5911-02",
            "0024-5911-01",
            "0024-5911-20"
          ],
          "nui": [
            "N0000193342",
            "N0000193341",
            "M0001357"
          ],
          "pharm_class_epc": [
            "Interleukin-4 Receptor alpha Antagonist [EPC]"
          ],
          "pharm_class_moa": [
            "Interleukin 4 Receptor alpha Antagonists [MoA]"
          ],
          "pharm_class_cs": [
            "Antibodies, Monoclonal [CS]"
          ],
          "unii": [
            "420K487FSG"
          ]
        }
      }
    ]
  }
},
{
  "_id": {
    "$oid": "68246feda116cc716124271a"
  },
  "safetyreportversion": 2,
  "safetyreportid": 19779685,
  "primarysourcecountry": "US",
  "occurcountry": "US",
  "transmissiondateformat": 102,
  "transmissiondate": {
    "$date": "2024-04-09T00:00:00.000Z"
  },
  "reporttype": 1,
  "serious": 2,
  "seriousnessdeath": 2,
  "seriousnesslifethreatening": 2,
  "seriousnesshospitalization": 2,
  "seriousnessdisabling": 2,
  "seriousnesscongenitalanomali": 2,
  "seriousnessother": 2,
  "receivedateformat": 102,
  "receivedate": {
    "$date": "2021-09-02T00:00:00.000Z"
  },
  "receiptdateformat": 102,
  "receiptdate": {
    "$date": "2024-03-06T00:00:00.000Z"
  },
  "fulfillexpeditecriteria": 2,
  "companynumb": "US-PUMA BIOTECHNOLOGY, LTD.-2021US001141",
  "primarysource": {
    "reportercountry": "US",
    "qualification": 3
  },
  "sender": {
    "sendertype": 2,
    "senderorganization": "FDA-Public Use"
  },
  "receiver": {
    "receivertype": 6,
    "receiverorganization": "FDA"
  },
  "patient": {
    "reaction": [
      {
        "reactionmeddraversionpt": 26.1,
        "reactionmeddrapt": "Diarrhoea",
        "reactionoutcome": 1
      }
    ],
    "drug": [
      {
        "drugcharacterization": 1,
        "medicinalproduct": "NERLYNX",
        "drugauthorizationnumb": 208051,
        "drugseparatedosagenumb": 1,
        "drugintervaldosageunitnumb": 1,
        "drugintervaldosagedefinition": 804,
        "drugdosagetext": "UNK, DAILY",
        "drugadministrationroute": 65,
        "drugindication": "HER2 positive breast cancer",
        "drugstartdateformat": 102,
        "drugstartdate": {
          "$date": "2021-02-02T00:00:00.000Z"
        },
        "actiondrug": 5,
        "drugrecurreadministration": 3,
        "drugadditional": 3,
        "activesubstance": {
          "activesubstancename": "NERATINIB"
        },
        "openfda": {
          "application_number": [
            "NDA208051"
          ],
          "brand_name": [
            "NERLYNX"
          ],
          "generic_name": [
            "NERATINIB"
          ],
          "manufacturer_name": [
            "Puma Biotechnology, Inc."
          ],
          "product_ndc": [
            "70437-240"
          ],
          "product_type": [
            "HUMAN PRESCRIPTION DRUG"
          ],
          "route": [
            "ORAL"
          ],
          "substance_name": [
            "NERATINIB MALEATE ANHYDROUS"
          ],
          "rxcui": [
            "1940648",
            "1940654"
          ],
          "spl_id": [
            "1484ac4d-7db5-fd0e-e063-6394a90a2b17"
          ],
          "spl_set_id": [
            "d1e41dcf-e82a-47c2-a0ad-6c6eef621834"
          ],
          "package_ndc": [
            "70437-240-18",
            "70437-240-26",
            "70437-240-33"
          ],
          "unii": [
            "9RM7XY23ZS"
          ]
        }
      }
    ],
    "summary": {
      "narrativeincludeclinical": "CASE EVENT DATE: 20210201",
      "case_event_date_extracted": {
        "$date": "2021-02-01T00:00:00.000Z"
      }
    }
  }
}]